Telix Pharmaceuticals (TLPPF) Non-Current Deferred Tax Liability (2024 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $43.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $43.3 million in Q2 2026; TTM through Jun 2026 was $43.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $44.7 million, up 671.33% from the prior year.
• Non-Current Deferred Tax Liability was $43.3 million for Q2 2026 at Telix Pharmaceuticals, down from $44.7 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $44.7 million in Q4 2025 and troughed at $6.1 million in Q4 2024.
• A 3-year average of $31.4 million and a median of $43.3 million in 2026 frame the typical range for Non-Current Deferred Tax Liability.
• The widest YoY moves for Non-Current Deferred Tax Liability: up 628.73% in 2025, down 628.73% in 2025.
• Over 3 years, Non-Current Deferred Tax Liability stood at $6.1 million in 2024, then surged by 628.73% to $44.7 million in 2025, then decreased by 3.14% to $43.3 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $43.3 million (Q2 2026), $44.7 million (Q4 2025), and $6.1 million (Q4 2024), per Business Quant data.